← Back to Search

Autologous Cell Therapy

ACP-01 for Critical Limb Ischemia

Phase 2
Waitlist Available
Research Sponsored by Hemostemix
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline vs. 1 year

Summary

This trial is testing a new treatment for people with a certain kind of heart disease who can't have surgery.

Eligible Conditions
  • Critical Limb Ischemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline vs. 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline vs. 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Wound Size, Amputation or Survival
Secondary study objectives
Pain Level
Ulcer Size
Other study objectives
Change From Baseline in Quality of Life

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: ACP-01Active Control1 Intervention
Injection into lower extremity
Group II: PlaceboPlacebo Group1 Intervention
Injection into lower extremity

Find a Location

Who is running the clinical trial?

HemostemixLead Sponsor
1 Previous Clinical Trials
95 Total Patients Enrolled
~6 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top